Page last updated: 2024-11-13
khg21834
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
KHG21834: has protective effect on amyloid beta-induced neurotoxicity in PC12 cells, cortical and mesencephalic neurons; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 43385006 |
SCHEMBL ID | 2789721 |
MeSH ID | M0515458 |
Synonyms (8)
Synonym |
---|
AKOS005880555 |
ethyl 2-(3-benzo[d]thiazole-2-ylureido)acetate |
MCZNQMUWWCOULO-UHFFFAOYSA-N |
SCHEMBL2789721 |
940938-64-7 |
khg21834 |
ethyl 2-(3-benzo[d]thiazol-2-ylureido)acetate |
ethyl 2-(1,3-benzothiazol-2-ylcarbamoylamino)acetate |
Research Excerpts
Treatment
Excerpt | Reference | Relevance |
---|---|---|
"Pretreatment with KHG21834 protected against Aβ-induced neuronal cell death and mitochondrial damage, and significantly restored GSH levels and the activities of catalase, superoxide dismutase, and glutathione peroxidase, and also suppressed the production of reactive oxygen species and protein oxidation." | ( Antioxidative effects of ethyl 2-(3-(benzo[d]thiazol-2-yl)ureido)acetate against amyloid β-induced oxidative cell death via NF-κB, GSK-3β and β-catenin signaling pathways in cultured cortical neurons. Cho, CH; Cho, SW; Choi, SY; Huh, JW; Kim, DW; Kim, EA, 2015) | 0.74 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.63
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |